Controlled comparisons are a cornerstone of clinical trials. A randomised concurrent control group is the gold standard but sometimes historical or non-concurrent controls may be considered for practical or other reasons. This talk will discuss historical, non-concurrent and other types of controls in clinical trials, focusing on their definition, advantages and disadvantages.
Ian Marschner is Professor of Biostatistics at the University of Sydney and Director of Biostatistics at the NHMRC Clinical Trials Centre. He has over 30 years experience working on clinical trials and methodological research. He is a Chief Investigator for the Australian Trials Methodology (AusTriM) Research Network, and formerly he was Head of Statistics at Macquarie University, Director of Biometrics at Pfizer and Associate Professor at Harvard.
Latest Resources
-
-
STInG Chat – What makes this trial great?
-
Platform trials: key features, when to use them and methodological challenges
-
Interim Data Sharing by Data Safety Monitoring Board: What to share, with whom, and why
-
Data Integrity Tool for assessing the integrity of randomised trials
-
The value of getting involved with ACTA STInG
-
Winner of the ACTA STInG Excellence in Trial Statistics award shares how ACTA STInG provided valuable networking opportunities during the pandemic
-
Data and Safety Monitoring Board (DSMB) Mentoring Program
-
ACTA Webinar – Developing a Best Practice Guide for Registry Based Trials
Latest Events
-
STInG Chat – What makes this trial great?
-
ACTA 2025 Clinical Trials and Registries Symposium
-
ACTA Webinar – Data Integrity Tool for assessing the integrity of randomised trials
-
ACTA Webinar – Developing a Best Practice Guide for Registry Based Trials
-
STInG Chat – How to build a career as a clinical trials biostatistician
-
Good Statistical Practice – GCP training for statisticians
-
STInG Chat: ‘Securing Funding: Tips and Tricks for Investigator Grants’